Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New outlook for treatment for bile duct cancer
drugs (stock image)
"We are excited by these results because these drugs are already being tested in clinical trials for other types of cancer and could be beneficial for patients with cholangiocarcinoma.”
Scientists testing experimental drugs that target a key tumour growth pathway

Those with cancer of the bile duct could soon be helped by a new class of experimental drug, a study led by the University of Edinburgh has revealed.

Scientists have discovered that a key pathway, known as wnt, is the driving force behind the growth of tumours in bile duct cancer.

Experimental drugs that block the wnt pathway are already being tested in patients with other cancers, but this is the first sign that bile duct cancer could also be treated in this way.

Researchers discovered that the treatment stopped the bile duct cancer cells from growing in the lab and shrank tumours in animals with the disease. They are now preparing to test whether these drugs will be effective in human patients.

The bile ducts are a series of tubes that drain toxins from the liver. Bile duct cancer, known as cholangiocarcinoma, is often diagnosed at an advanced stage, making it very difficult to treat with surgery. It typically does not respond to chemotherapy and fewer that one in twenty patients will survive for five years after diagnosis.

Professor Stuart Forbes from the MRC Centre for Regenerative Medicine at the University of Edinburgh, said: “We are excited by these results because these drugs are already being tested in clinical trials for other types of cancer and could be beneficial for patients with cholangiocarcinoma.”
 
Dr Luke Boulter from the MRC Human Genetics Unit at the University of Edinburgh, said: “Identifying the signals that control bile duct cancer’s growth will allow us to design better treatments that are urgently needed.”
 
Helen Moremont, chairman trustee of AMMF, The Cholangiocarcinoma Charity, said: “This is potentially very exciting. Cholangiocarcinoma is an under-researched, much neglected but truly devastating disease, so it is good to see progress being made in novel areas.  We are hopeful that this research work with wnt will provide a real step forward towards a clinical trial and some long awaited possible improvements in treatment.”  

Become a member or log in to add this story to your CPD history

Birmingham Dogs Home makes urgent appeal

News Story 1
 Birmingham Dogs Home has issued an urgent winter appeal as it faces more challenges over the Christmas period.

The rescue centre has seen a dramatic increase in dogs coming into its care, and is currently caring for over 200 dogs. With rising costs and dropping temperatures, the charity is calling for urgent support.

It costs the charity £6,000 per day to continue its work.

Fi Harrison, head of fundraising and communications, said: "It's heart-breaking for our team to see the conditions some dogs arrive in. We really are their last chance and hope of survival."

More information about the appeal can be found here

Click here for more...
News Shorts
Avian flu confirmed at premises in Cornwall

A case of highly pathogenic avian influenza H5N1 has been detected in commercial poultry at a premises near Rosudgeon, Cornwall.

All poultry on the infected site will be humanely culled, and a 3km protection zone and 10km surveillance zone have been put in place. Poultry and other captive birds in the 3km protection zone must be housed.

The case is the second avian flu case confirmed in commercial poultry this month. The H5N5 strain was detected in a premises near Hornsea, East Riding of Yorkshire, in early November. Before then, the disease had not been confirmed in captive birds in England since February.

The UK chief veterinary officer has urged bird keepers to remain alert and practise robust biosecurity.

A map of the disease control zones can be found here.